Ha Wook Park
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ha Wook Park has a total of 65 co-authors. Here are the top co-authors by number of shared publications:
- Jae-Hwan Lee
Division of Cardiology, Chungnam National University Sejong Hospital, Sejong, Korea
3 shared publications - Byeong-Keuk Kim
Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Korea
2 shared publications - Jang Hoon Lee
Department of Internal Medicine, Kyungpook National University Hospital, School of Medicine, Kyungpook National University, Daegu, Korea
2 shared publications - Je Sang Kim
Division of Cardiology, Department of Internal Medicine, Bucheon Sejong Hospital, Bucheon, Korea
2 shared publications - Ji-Yong Jang
National Health Insurance Service Ilsan Hospital
2 shared publications - Jun-Won Lee
Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Korea
2 shared publications
Latest Publications
- Open Access
- 1 January 2027
- Published by XMLink in Korean Circulation Journal
- Vol. 57
Contemporary Clinical Practices in Korean Patients With Coronary Chronic Total Occlusion: Results From the K-CTO Nationwide Retrospective Registry
Cha JJ, et al. Korean Circ J. 2027 ;57:e4. https://doi.org/10.4070/kcj.2025.0412
- 1 January 2027
- Published by XMLink in Korean Circulation Journal
- Vol. 57
Open AccessContemporary Clinical Practices in Korean Patients With Coronary Chronic Total Occlusion: Results From the K-CTO Nationwide Retrospective Registry
Cha JJ, et al. Korean Circ J. 2027 ;57:e4. https://doi.org/10.4070/kcj.2025.0412
- Open Access
- 1 January 2026
- Published by XMLink in Korean Circulation Journal
- Vol. 56 (9) , 776
Intravascular Ultrasound-Guided Percutaneous Coronary Intervention for Severely Calcified Lesions Requiring Rotational Atherectomy
Jang DH, et al. Korean Circ J. 2026 ;56:e60. https://doi.org/10.4070/kcj.2025.0255
- 1 January 2026
- Published by XMLink in Korean Circulation Journal
- Vol. 56 (9) , 776
Open AccessIntravascular Ultrasound-Guided Percutaneous Coronary Intervention for Severely Calcified Lesions Requiring Rotational Atherectomy
Jang DH, et al. Korean Circ J. 2026 ;56:e60. https://doi.org/10.4070/kcj.2025.0255
- Open Access
- 12 August 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (16) , e041564
Twenty‐Four–Month Outcomes of Intravascular Ultrasound‐Guided Drug‐Coated Balloon Angioplasty for Femoropopliteal Artery Disease
Background: The IVUS‐DCB (Intravascular Ultrasound‐Guided Drug‐Coated Balloon Angioplasty for Femoropopliteal Artery Disease) trial found that intravascular ultrasound (IVUS)–guided drug‐coated balloon (DCB) angioplasty was associated with superior 12‐month outcomes, compared with conventional angiography‐guided DCB angioplasty. However, the durability of these benefits remains uncertain. The aim of this study was to compare the 24‐month outcomes of IVUS‐guided versus angiography‐guided DCB angioplasty for femoropopliteal artery disease. Methods: This extended study analyzed a total of 237 patients who were previously randomized into IVUS‐guidance (n=119) or angiography‐guidance (n=118) groups in the original IVUS‐DCB trial. The 24‐month clinical efficacy outcomes included freedom from clinically driven target lesion revascularization, sustained clinical and hemodynamic improvements, and freedom from major amputation. Results: At 24‐month follow‐up, the IVUS‐guidance group exhibited significantly higher rates of freedom from clinically driven target lesion revascularization (87.4% versus 78.0%; hazard ratio, 0.46 [95% CI, 0.24–0.88]; P =0.02), sustained clinical improvement (82.4% versus 71.2%, P =0.02), and sustained hemodynamic improvement (74.8% versus 61.0%, P =0.01), compared with the angiography‐guidance group. No major amputations occurred in either group during the 24‐month follow‐up. There were no significant differences in safety outcomes between groups, including all‐cause death, cardiovascular death, and major bleeding. Conclusions: At 24‐month follow‐up, IVUS‐guided DCB angioplasty for femoropopliteal artery disease continued to demonstrate superior outcomes, compared with angiography‐guided DCB angioplasty, in terms of freedom from clinically driven target lesion revascularization, sustained clinical improvement, and sustained hemodynamic improvement.
- 12 August 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (16) , e041564
Open AccessTwenty‐Four–Month Outcomes of Intravascular Ultrasound‐Guided Drug‐Coated Balloon Angioplasty for Femoropopliteal Artery Disease
Background: The IVUS‐DCB (Intravascular Ultrasound‐Guided Drug‐Coated Balloon Angioplasty for Femoropopliteal Artery Disease) trial found that intravascular ultrasound (IVUS)–guided drug‐coated balloon (DCB) angioplasty was associated with superior 12‐month outcomes, compared with conventional angiography‐guided DCB angioplasty. However, the durability of these benefits remains uncertain. The aim of this study was to compare the 24‐month outcomes of IVUS‐guided versus angiography‐guided DCB angioplasty for femoropopliteal artery disease. Methods: This extended study analyzed a total of 237 patients who were previously randomized into IVUS‐guidance (n=119) or angiography‐guidance (n=118) groups in the original IVUS‐DCB trial. The 24‐month clinical efficacy outcomes included freedom from clinically driven target lesion revascularization, sustained clinical and hemodynamic improvements, and freedom from major amputation. Results: At 24‐month follow‐up, the IVUS‐guidance group exhibited significantly higher rates of freedom from clinically driven target lesion revascularization (87.4% versus 78.0%; hazard ratio, 0.46 [95% CI, 0.24–0.88]; P =0.02), sustained clinical improvement (82.4% versus 71.2%, P =0.02), and sustained hemodynamic improvement (74.8% versus 61.0%, P =0.01), compared with the angiography‐guidance group. No major amputations occurred in either group during the 24‐month follow‐up. There were no significant differences in safety outcomes between groups, including all‐cause death, cardiovascular death, and major bleeding. Conclusions: At 24‐month follow‐up, IVUS‐guided DCB angioplasty for femoropopliteal artery disease continued to demonstrate superior outcomes, compared with angiography‐guided DCB angioplasty, in terms of freedom from clinically driven target lesion revascularization, sustained clinical improvement, and sustained hemodynamic improvement.